RENAGEL Drug Patent Profile

When do Renagel patents expire, and what generic alternatives are available?

Renagel is a drug marketed by Genzyme and is included in two NDAs.

The generic ingredient in RENAGEL is sevelamer hydrochloride. There are thirty-two drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the sevelamer hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Renagel

A generic version of RENAGEL was approved as sevelamer hydrochloride by GLENMARK PHARMS LTD on February 8^th, 2019.

Summary for RENAGEL

US Patents:	0
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	50
Clinical Trials:	19
Drug Prices:	Drug price information for RENAGEL
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for RENAGEL
What excipients (inactive ingredients) are in RENAGEL?	RENAGEL excipients list
DailyMed Link:	RENAGEL at DailyMed

See drug prices for RENAGEL

See drug sales revenues for RENAGEL

Recent Clinical Trials for RENAGEL

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Medical Universtity of Lodz	Phase 4
Medical University of Lodz	Phase 4
Shire	Phase 4

See all RENAGEL clinical trials

Paragraph IV (Patent) Challenges for RENAGEL

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
RENAGEL	Tablets	sevelamer hydrochloride	400 mg and 800 mg	021179	1	2008-05-22

US Patents and Regulatory Information for RENAGEL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Genzyme	RENAGEL	sevelamer hydrochloride	CAPSULE;ORAL	020926-001	Oct 30, 1998		DISCN	No	No
Genzyme	RENAGEL	sevelamer hydrochloride	TABLET;ORAL	021179-001	Jul 12, 2000	AB	RX	Yes	No
Genzyme	RENAGEL	sevelamer hydrochloride	TABLET;ORAL	021179-002	Jul 12, 2000	AB	RX	Yes	Yes

Expired US Patents for RENAGEL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Genzyme	RENAGEL	sevelamer hydrochloride	TABLET;ORAL	021179-002	Jul 12, 2000	6,509,013
Genzyme	RENAGEL	sevelamer hydrochloride	CAPSULE;ORAL	020926-001	Oct 30, 1998	5,496,545
Genzyme	RENAGEL	sevelamer hydrochloride	TABLET;ORAL	021179-002	Jul 12, 2000	5,496,545
Genzyme	RENAGEL	sevelamer hydrochloride	TABLET;ORAL	021179-002	Jul 12, 2000	6,733,780
Genzyme	RENAGEL	sevelamer hydrochloride	TABLET;ORAL	021179-001	Jul 12, 2000	6,509,013

EU/EMA Drug Approvals for RENAGEL

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Genzyme Europe BV	Tasermity	sevelamer hydrochloride	EMEA/H/C/003968Tasermity is indicated for the control of hyperphosphataemia in adult patients receiving haemodialysis or peritoneal dialysis. Sevelamer hydrochloride should be used within the context of a multiple therapeutic approach, which could include calcium supplements, 1,25 dihydroxy Vitamin D3 or one of its analogues to control the development of renal bone disease.,	Withdrawn	no	no	no	2015-02-25

International Patents for RENAGEL

See the table below for patents covering RENAGEL around the world.

Country	Patent Number	Title	Estimated Expiration
Portugal	716606
Australia	1088701
Poland	364888
World Intellectual Property Organization (WIPO)	9639156
Netherlands	300080

Supplementary Protection Certificates for RENAGEL

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0716606	SPC/GB02/011	United Kingdom		PRODUCT NAME: SEVELAMER; REGISTERED: UK EU/1/99/120/001-004 20000202
0716606	CA 2002 00003	Denmark
0716606	C300080	Netherlands		PRODUCT NAME: SEVELAMER, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AAN- VAARDBAAR ZOUT, IN HET BIJZONDER SEVELAMER HYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/99/123/001-00420000128 20000128
0716606	6/2002	Austria		PRODUCT NAME: SEVELAMER SOWIE DESSEN PHARMAZEUTISCH VERTRAEGLICHEN SALZE; REGISTRATION NO/DATE: EU/1/99/123/001 - EU/1/99/123/004 20000128
0716606	C00716606/01	Switzerland		PRODUCT NAME: SEVELAMER; REGISTRATION NUMBER/DATE: SWISSMEDIC 56297 10.02.2004

Market Dynamics and Financial Trajectory for RENAGEL

Last updated: January 11, 2026

Executive Summary

Renagel (sevelamer hydrochloride) is a non-calcium, phosphate-binding drug approved for managing hyperphosphatemia in patients with chronic kidney disease (CKD) and end-stage renal disease (ESRD). Since its FDA approval in 1998, it has become a critical therapy within nephrology, vying with calcium-based phosphate binders. Its unique dual mechanism—binding phosphate without adding calcium—and favorable safety profile position it within a competitive landscape characterized by evolving clinical guidelines, emerging competitors, and demographic shifts in CKD prevalence.

This analysis delineates the market currents, revenue potential, competitive threats, and regulatory influences shaping Renagel’s financial trajectory over the coming decade. With an emphasis on market size, growth drivers, and challenges, stakeholders can better anticipate Renagel’s positioning and strategic opportunities.

---

1. Market Overview and Size

Global CKD and ESRD Populations

• Global CKD prevalence: Approx. 9.1% (~700 million individuals) [1].
• ESRD incidence: ~2 million patients globally, with approximately 750,000 in the U.S. [2].
• Projected growth: The CKD population is expanding due to aging demographics, diabetes, and hypertension. The ESRD population is expected to grow at a CAGR of 4-6% over the next decade [3].

Market for Phosphate Binders

• Market valuation: Estimated at $2.5 billion in 2022, with projected CAGR of 6% through 2030 [4].
• Share of global phosphate binder market: North America dominates (~50%), followed by Europe (~25%), Asia-Pacific (~20%), with the rest of the world accounting for the remainder.

Sevelamer Market Share

• Market share: Estimated at 30-40% among non-calcium phosphate binders in the U.S. [5].
• Pricing model: Typically, $400–$800/month per patient, varying by dosage and formulation.

---

2. Key Market Drivers

a. Demographic Trends

• Aging populations internationally are driving CKD and ESRD prevalence.
• Rising incidence of diabetes and hypertension—primary CKD causes—accelerates market growth.

b. Clinical Guidelines and Acceptance

• KDIGO (Kidney Disease: Improving Global Outcomes) recommends phosphate control, emphasizing non-calcium binders in specific populations, boosting Renagel’s uptake [6].
• Clinicians favor non-calcium options due to risks of vascular calcification associated with calcium-based binders.

c. Product Profile and Differentiation

• Advantages: Binds phosphate without raising calcium levels; reduces vascular calcification risk.
• Limitations: Gastrointestinal side effects, pill burden (up to 12 grams daily), and cost.

d. Patent and Regulatory Environment

• Patent expirations: Limited, but formulation patents have delayed generics in key markets.
• Regulatory landscape: Strict guidelines for safety and efficacy; no recent FDA label updates but ongoing post-marketing surveillance.

---

3. Competitive Landscape and Challenges

Competitor	Product Name	Market Share	Mechanism	Regulatory Status	Pricing
Phosphate Bindings	Calcium acetate (PhosLo)	~40%	Calcium-based	OTC, prescription	~$200/month
	Sevelamer carbonate (Renvela)	Same as Renagel	Same mechanism, different salt	FDA approved 2007	$300-$600/month
Non-calcium Binders	Lanthanum carbonate (Fosrenol)	~10-15%	Lanthanum-based	Prescription	~$400/month
	Ferric citrate (Auryxia)	Emerging	Iron-based	Prescription	~$300/month

• Patent expiration: Generic versions of Renagel/Renvela are pending or available in select markets, pressuring pricing.

Key Challenges

• Cost and Pill Burden: High medication costs and high pill count hinder adherence, especially outside the U.S.
• Emergence of Generics: Price erosion from generics threatens profit margins.
• New Therapies: Innovations like phosphate-releasing agents or novel drugs could disrupt traditional binding strategies.
• Regulatory Restrictions: Varying acceptance of non-calcium binders in different jurisdictions affects market penetration.

---

4. Financial Trajectory and Revenue Forecasts

Year	Estimated Revenue (USD millions)	Assumptions	Notes
2022	~$400	Base case with steady uptake	Market saturation in mature markets; slight growth due to demographic expansion
2025	~$600	Growth driven by expanding CKD populations and clinical guideline support	Expansion into emerging markets
2030	~$800	Penetration of Asia-Pacific markets; increased acceptance of non-calcium binders	Introduction of new formulations or combination therapies

Forecasting Factors

• Market Growth Rate: 6-8% annually, driven by demographic factors.
• Market Share Trends: Potential decline if generic competition intensifies unless differentiated through formulations or combination therapies.
• Pricing Dynamics: Possible decrease of 10-15% due to generics and price negotiations.

---

5. Regulatory and Policy Influences

• Reimbursement policies: In the U.S., Medicare and private insurers reimburse based on formulary placement; shifting policies may impact sales.
• Global Access: Differing approvals and reimbursement schemes across countries affect market trajectory.
• Clinical Evidence: Meta-analyses and guidelines favoring non-calcium binders bolster demand for Renagel.

---

6. Comparative Analysis with Other Phosphate Binders

Parameter	Renagel	Calcium Binders	Lanthanum	Ferric Citrate
Mechanism	Phosphate binding without calcium	Calcium-based	Lanthanum ions	Iron-based
Efficacy	High	High	High	Moderate
Safety Concerns	GI side effects, pill burden	Vascular calcification, hypercalcemia	GI irritation, rare toxicity	Iron overload risk
Cost	$400–$800/month	~$200/month	~$400/month	~$300/month
Regulatory Status	Approved in US, others	OTC/Prescription	Prescription	Prescription

---

7. Future Outlook and Strategic Considerations

• Innovation: Development of combination therapies or sustained-release formulations may improve adherence.
• Market Expansion: Entering emerging markets requires navigating local regulations and affordability constraints.
• Cost-Containment: Price reductions from generic entries may necessitate diversification or value-added formulations.
• Clinical Evidence: Ongoing trials assessing hard endpoints (mortality, vascular calcification) will influence clinician choice and regulatory policies.

---

Key Takeaways

• Market Growth: Into a $3 billion+ global phosphate binder market, driven primarily by demographic aging and CKD prevalence.
• Competitive Position: Renagel maintains a significant share due to safety profile and clinical acceptance but faces erosion from generics and newer therapies.
• Revenue Outlook: Moderate growth trajectory, with potential acceleration through emerging markets and formulation innovation.
• Challenges: Cost, pill burden, patent expiry, and competitive pressure require strategic agility.
• Opportunities: Expanding clinical evidence, pharmacoeconomic benefits, and market penetration can sustain and enhance Renagel's financial trajectory.

---

FAQs

1. How does Renagel compare to calcium-based phosphate binders in terms of efficacy?

Renagel has demonstrated comparable phosphate-lowering efficacy to calcium-based binders, with the added benefit of reducing vascular calcification risk, which is a notable advantage in high-risk CKD patients [6].

2. What are the primary factors influencing Renagel’s market share growth?

Market share depends on demographic trends, clinical guidelines favoring non-calcium binders, cost competitiveness, and the advent of newer therapies. Adherence issues due to pill burden and cost also significantly impact uptake.

3. Are generic versions of Renagel available globally?

Yes, several markets are seeing generic versions approved or in development following patent expirations. The presence of generics often leads to substantial price reductions and market share shifts.

4. How might emerging therapies impact Renagel's financial prospects?

Innovations such as phosphate-releasing agents, advanced dialysis techniques, or targeted molecular therapies could erode Renagel's market share unless it adapts through formulation improvements or combination strategies.

5. What role do regulatory policies play in Renagel’s market expansion?

Strict regulations and reimbursement policies influence market access and profitability. Supportive policies and clinical guidelines that endorse non-calcium binders can significantly bolster Renagel’s prospects.

---

References

[1] Bikbov B, et al. Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis. Lancet Glob Health. 2020;8(5):e699-e712.

[2] U.S. Renal Data System. 2022 USRDS Annual Data Report.

[3] Neuen BL, et al. The global burden of chronic kidney disease: a meta-analysis. Lancet. 2017;390(10105):15-29.

[4] MarketWatch. Phosphate Binder Market Size, Share & Trends Analysis Report, 2022.

[5] IQVIA. Nephrology drug market share report, 2022.

[6] KDIGO. KDIGO 2017 Clinical Practice Guideline Update for CKD-MBD.

---

By understanding these dynamics, pharmaceutical stakeholders can optimize strategic planning, product positioning, and investment decisions regarding Renagel within the evolving nephrology pharmaceutical landscape.